Technology plays a central role in PGT-A
More advanced technology has been shown to produce more reliable results.
Over the years, advances in technology have played a pivotal role in the evolution of PGT. These technological innovations have driven improvements in accuracy, sensitivity and specificity of PGT-A results.
We are proud to announce the next leap in PGT-A technology. Our esteemed scientific experts have developed a revolutionary new platform in PGT-A analysis and reporting.
CooperGenomics PGT-A is performed via Next-Generation Sequencing technology and provides the best detection of:
- Partial (segmental) aneuploidy
- Unbalanced translocations
- Some polyploidies
CooperGenomics’ revolutionary approach to PGT-A
A new PGT-A interpretation and reporting platform
- Innovative tool that leverages the data accumulated over the history of PGT-A at CooperGenomics
- Only analysis platform in the field built from a truth data set of known euploid pregnancies (~1000)
- Allows for transfer decisions based on mathematical and statistical predictions, removing the limitation of human interaction, subjectivity, and error
- Employs machine learning to enable continuous controlled improvement
- Improves signal clarity, increasing accuracy to ensure optimal sensitivity and specificity*
*Internal CooperGenomics, data on file, 2018
CooperGenomics PGTaiSM Technology
How PGT-A Works
Mosaicism occurs when an embryo contains both euploid and aneuploid cells as a result of errors in cell division (mitosis) made during embryo growth. With the advent of high-resolution PGT-A technology, mosaicism has emerged alongside euploidy and aneuploidy as a third category of potential PGT-A results.
|Number of chromosomes per cell||Normal||Abnormal||Mixed (some normal & some abnormal)|
|Likelihood of producing a successful pregnancy||High||Very unlikely||Low, but possible|
|Recommended for transfer||Yes||No||No; provider may consider transfer if no euploid embryos available|
Unlike traditional PGT-A technologies, CooperGenomics’ PGT-A has been validated to reliably detect mosaic samples with 20-80% aneuploid cells. While more research is required to fully understand the clinical implications of embryonic mosaicism, current studies show that mosaic embryos implant less and miscarry more than euploid embryos, but some mosaic embryos maintain their viability and can lead to live birth. Given that, experts recommend considering mosaic embryos for transfer in cases where no euploid embryos are available and prioritizing mosaics based on the level of aneuploidy and chromosome impacted.
Our team is pioneering cutting-edge research and contributing to key scientific discussions and publications to drive a better understanding of the impact of mosaicism.
Reporting and Counseling
PGT-A reports are typically available within 14 days of sample receipt at a CooperGenomics laboratory, though we are happy to work with your team to accommodate next day results for fresh transfers, given prior notice. Reports are released to the ordering provider, with results clearly presented on the first page(s) and euploid/normal results highlighted. We are proud to be one of the first laboratories standardly reporting mosaic results, categorized as low-level mosaic, high-level mosaic, or complex abnormal.
CooperGenomics’ expert team of specially trained, board-certified genetic counselors is available for you and your patients at every point in the PGT-A testing process.
Introducing PGT Simplified
CooperGenomicsSM brings you and your patients a better PGT experience
POWERED BY ENGAGEDMD+